APO Research
Talk to an analyst

APO RESEARCH · REPORT

DPT Series Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global DPT Series Vaccine Market Outlook and Growth Opportunities 2026

29 December 2025197 pages

Choose your research edition.

Industry ResearchDPT Series Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal DPT Series Vaccine Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal DPT Series Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DPT Series Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal DPT Series Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global DPT Series Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for DPT Series Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DPT Series Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DPT Series Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the DPT Series Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the DPT Series Vaccine market include AJ Vaccines, GSK, Panacea Biotec, Sanofi, Hualan Biological Vaccine, BioKangtai, CanSino Biologics, Walvax Biotechnology and CNBG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DPT Series Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DPT Series Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DPT Series Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DPT Series Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

DPT Series Vaccine Segment by Company

AJ Vaccines

GSK

Panacea Biotec

Sanofi

Hualan Biological Vaccine

BioKangtai

CanSino Biologics

Walvax Biotechnology

CNBG

Chongqing Zhifei Biological Products

DPT Series Vaccine Segment by Type

Absorbed Acellular Diphtheria-Tetanus-Pertussis Combined Vaccine

Absorbed Tetanus Vaccine

Absorbed Diphtheria-Tetanus Combined Vaccine

DTP-IPV-Hib Pentavalent Vaccine

DTP-Hib Quadruple Vaccine

DPT Series Vaccine Segment by Application

Adults

Children

DPT Series Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global DPT Series Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions DPT Series Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify DPT Series Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze DPT Series Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPT Series Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DPT Series Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPT Series Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DPT Series Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global DPT Series Vaccine industry.

Chapter 3: Detailed analysis of DPT Series Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of DPT Series Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of DPT Series Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. DPT Series Vaccine Industry Trends Table 2. DPT Series Vaccine Industry Drivers Table 3. DPT Series Vaccine Industry Opportunities and Challenges Table 4. DPT Series Vaccine Industry Restraints Table 5. Global DPT Series Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global DPT Series Vaccine Revenue Share by Company (2021-2026) Table 7. Global DPT Series Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global DPT Series Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global DPT Series Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global DPT Series Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global DPT Series Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global DPT Series Vaccine Company, Product Type & Application Table 13. Global DPT Series Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global DPT Series Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Absorbed Acellular Diphtheria-Tetanus-Pertussis Combined Vaccine Table 18. Significant Companies of Absorbed Tetanus Vaccine Table 19. Significant Companies of Absorbed Diphtheria-Tetanus Combined Vaccine Table 20. Significant Companies of DTP-IPV-Hib Pentavalent Vaccine Table 21. Significant Companies of DTP-Hib Quadruple Vaccine Table 22. Global DPT Series Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global DPT Series Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 24. Global DPT Series Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 25. Global DPT Series Vaccine Sales Volume Share by Type (2021-2026) Table 26. Global DPT Series Vaccine Sales Volume Share by Type (2027-2032) Table 27. Global DPT Series Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global DPT Series Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global DPT Series Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global DPT Series Vaccine Sales Value Share by Type (2021-2026) Table 31. Global DPT Series Vaccine Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Adults Table 33. Significant Companies of Children Table 34. Global DPT Series Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global DPT Series Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 36. Global DPT Series Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 37. Global DPT Series Vaccine Sales Volume Share by Application (2021-2026) Table 38. Global DPT Series Vaccine Sales Volume Share by Application (2027-2032) Table 39. Global DPT Series Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global DPT Series Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global DPT Series Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global DPT Series Vaccine Sales Value Share by Application (2021-2026) Table 43. Global DPT Series Vaccine Sales Value Share by Application (2027-2032) Table 44. Global DPT Series Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global DPT Series Vaccine Sales by Region (2021-2026) & (K Units) Table 46. Global DPT Series Vaccine Sales Market Share by Region (2021-2026) Table 47. Global DPT Series Vaccine Sales by Region (2027-2032) & (K Units) Table 48. Global DPT Series Vaccine Sales Market Share by Region (2027-2032) Table 49. Global DPT Series Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global DPT Series Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global DPT Series Vaccine Sales Value Share by Region (2021-2026) Table 52. Global DPT Series Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global DPT Series Vaccine Sales Value Share by Region (2027-2032) Table 54. Global DPT Series Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global DPT Series Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global DPT Series Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global DPT Series Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global DPT Series Vaccine Sales by Country (2021-2026) & (K Units) Table 59. Global DPT Series Vaccine Sales Market Share by Country (2021-2026) Table 60. Global DPT Series Vaccine Sales by Country (2027-2032) & (K Units) Table 61. Global DPT Series Vaccine Sales Market Share by Country (2027-2032) Table 62. Global DPT Series Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global DPT Series Vaccine Sales Value Market Share by Country (2021-2026) Table 64. Global DPT Series Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global DPT Series Vaccine Sales Value Market Share by Country (2027-2032) Table 66. AJ Vaccines Company Information Table 67. AJ Vaccines Business Overview Table 68. AJ Vaccines DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. AJ Vaccines DPT Series Vaccine Product Portfolio Table 70. AJ Vaccines Recent Development Table 71. GSK Company Information Table 72. GSK Business Overview Table 73. GSK DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. GSK DPT Series Vaccine Product Portfolio Table 75. GSK Recent Development Table 76. Panacea Biotec Company Information Table 77. Panacea Biotec Business Overview Table 78. Panacea Biotec DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Panacea Biotec DPT Series Vaccine Product Portfolio Table 80. Panacea Biotec Recent Development Table 81. Sanofi Company Information Table 82. Sanofi Business Overview Table 83. Sanofi DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sanofi DPT Series Vaccine Product Portfolio Table 85. Sanofi Recent Development Table 86. Hualan Biological Vaccine Company Information Table 87. Hualan Biological Vaccine Business Overview Table 88. Hualan Biological Vaccine DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Hualan Biological Vaccine DPT Series Vaccine Product Portfolio Table 90. Hualan Biological Vaccine Recent Development Table 91. BioKangtai Company Information Table 92. BioKangtai Business Overview Table 93. BioKangtai DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. BioKangtai DPT Series Vaccine Product Portfolio Table 95. BioKangtai Recent Development Table 96. CanSino Biologics Company Information Table 97. CanSino Biologics Business Overview Table 98. CanSino Biologics DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. CanSino Biologics DPT Series Vaccine Product Portfolio Table 100. CanSino Biologics Recent Development Table 101. Walvax Biotechnology Company Information Table 102. Walvax Biotechnology Business Overview Table 103. Walvax Biotechnology DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Walvax Biotechnology DPT Series Vaccine Product Portfolio Table 105. Walvax Biotechnology Recent Development Table 106. CNBG Company Information Table 107. CNBG Business Overview Table 108. CNBG DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. CNBG DPT Series Vaccine Product Portfolio Table 110. CNBG Recent Development Table 111. Chongqing Zhifei Biological Products Company Information Table 112. Chongqing Zhifei Biological Products Business Overview Table 113. Chongqing Zhifei Biological Products DPT Series Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Chongqing Zhifei Biological Products DPT Series Vaccine Product Portfolio Table 115. Chongqing Zhifei Biological Products Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. DPT Series Vaccine Distributors List Table 119. DPT Series Vaccine Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. DPT Series Vaccine Product Image Figure 2. Global DPT Series Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global DPT Series Vaccine Sales (2021-2032) & (K Units) Figure 5. Global DPT Series Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global DPT Series Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Absorbed Acellular Diphtheria-Tetanus-Pertussis Combined Vaccine Image Figure 10. Absorbed Tetanus Vaccine Image Figure 11. Absorbed Diphtheria-Tetanus Combined Vaccine Image Figure 12. DTP-IPV-Hib Pentavalent Vaccine Image Figure 13. DTP-Hib Quadruple Vaccine Image Figure 14. Global DPT Series Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global DPT Series Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global DPT Series Vaccine Sales Volume Share by Type (2021-2032) Figure 17. Global DPT Series Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global DPT Series Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global DPT Series Vaccine Sales Value Share by Type (2021-2032) Figure 20. Adults Image Figure 21. Children Image Figure 22. Global DPT Series Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global DPT Series Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global DPT Series Vaccine Sales Volume Share by Application (2021-2032) Figure 25. Global DPT Series Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global DPT Series Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global DPT Series Vaccine Sales Value Share by Application (2021-2032) Figure 28. Global DPT Series Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global DPT Series Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global DPT Series Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global DPT Series Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. North America DPT Series Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Europe DPT Series Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific DPT Series Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. South America DPT Series Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa DPT Series Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa DPT Series Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt DPT Series Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. DPT Series Vaccine Value Chain Figure 127. Manufacturing Cost Structure Figure 128. DPT Series Vaccine Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Absorbed Acellular Diphtheria-Tetanus-Pertussis Combined Vaccine
  • Absorbed Tetanus Vaccine
  • Absorbed Diphtheria-Tetanus Combined Vaccine
  • DTP-IPV-Hib Pentavalent Vaccine
  • DTP-Hib Quadruple Vaccine
Applications
  • Adults
  • Children
Companies covered
  • AJ Vaccines
  • GSK
  • Panacea Biotec
  • Sanofi
  • Hualan Biological Vaccine
  • BioKangtai
  • CanSino Biologics
  • Walvax Biotechnology
  • CNBG
  • Chongqing Zhifei Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DPT Series Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global DPT Series Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global DPT Series Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 DPT Series Vaccine Market Dynamics
  1. 2.1 DPT Series Vaccine Industry Trends
  2. 2.2 DPT Series Vaccine Industry Drivers
  3. 2.3 DPT Series Vaccine Industry Opportunities and Challenges
  4. 2.4 DPT Series Vaccine Industry Restraints
3 DPT Series Vaccine Market by Company
  1. 3.1 Global DPT Series Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global DPT Series Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global DPT Series Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global DPT Series Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global DPT Series Vaccine Company Ranking (2024-2026)
  6. 3.6 Global DPT Series Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global DPT Series Vaccine Company Product Type and Application
  8. 3.8 Global DPT Series Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global DPT Series Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 DPT Series Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 DPT Series Vaccine Market by Type
  1. 4.1 DPT Series Vaccine Type Introduction
  2. 4.1.1 Absorbed Acellular Diphtheria-Tetanus-Pertussis Combined Vaccine
  3. 4.1.2 Absorbed Tetanus Vaccine
  4. 4.1.3 Absorbed Diphtheria-Tetanus Combined Vaccine
  5. 4.1.4 DTP-IPV-Hib Pentavalent Vaccine
  6. 4.1.5 DTP-Hib Quadruple Vaccine
  7. 4.2 Global DPT Series Vaccine Sales Volume by Type
  8. 4.2.1 Global DPT Series Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global DPT Series Vaccine Sales Volume by Type (2021-2032)
  10. 4.2.3 Global DPT Series Vaccine Sales Volume Share by Type (2021-2032)
  11. 4.3 Global DPT Series Vaccine Sales Value by Type
  12. 4.3.1 Global DPT Series Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global DPT Series Vaccine Sales Value by Type (2021-2032)
  14. 4.3.3 Global DPT Series Vaccine Sales Value Share by Type (2021-2032)
5 DPT Series Vaccine Market by Application
  1. 5.1 DPT Series Vaccine Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global DPT Series Vaccine Sales Volume by Application
  5. 5.2.1 Global DPT Series Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global DPT Series Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global DPT Series Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global DPT Series Vaccine Sales Value by Application
  9. 5.3.1 Global DPT Series Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global DPT Series Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global DPT Series Vaccine Sales Value Share by Application (2021-2032)
6 DPT Series Vaccine Regional Sales and Value Analysis
  1. 6.1 Global DPT Series Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DPT Series Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global DPT Series Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global DPT Series Vaccine Sales by Region (2027-2032)
  5. 6.3 Global DPT Series Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global DPT Series Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global DPT Series Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global DPT Series Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global DPT Series Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America DPT Series Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America DPT Series Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe DPT Series Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe DPT Series Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific DPT Series Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific DPT Series Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America DPT Series Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America DPT Series Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa DPT Series Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa DPT Series Vaccine Sales Value Share by Country, 2025 VS 2032
7 DPT Series Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global DPT Series Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global DPT Series Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global DPT Series Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global DPT Series Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global DPT Series Vaccine Sales by Country (2027-2032)
  6. 7.4 Global DPT Series Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global DPT Series Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global DPT Series Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt DPT Series Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt DPT Series Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt DPT Series Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AJ Vaccines
  2. 8.1.1 AJ Vaccines Company Information
  3. 8.1.2 AJ Vaccines Business Overview
  4. 8.1.3 AJ Vaccines DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AJ Vaccines DPT Series Vaccine Product Portfolio
  6. 8.1.5 AJ Vaccines Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK DPT Series Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Panacea Biotec
  14. 8.3.1 Panacea Biotec Company Information
  15. 8.3.2 Panacea Biotec Business Overview
  16. 8.3.3 Panacea Biotec DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Panacea Biotec DPT Series Vaccine Product Portfolio
  18. 8.3.5 Panacea Biotec Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi DPT Series Vaccine Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Hualan Biological Vaccine
  26. 8.5.1 Hualan Biological Vaccine Company Information
  27. 8.5.2 Hualan Biological Vaccine Business Overview
  28. 8.5.3 Hualan Biological Vaccine DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hualan Biological Vaccine DPT Series Vaccine Product Portfolio
  30. 8.5.5 Hualan Biological Vaccine Recent Developments
  31. 8.6 BioKangtai
  32. 8.6.1 BioKangtai Company Information
  33. 8.6.2 BioKangtai Business Overview
  34. 8.6.3 BioKangtai DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 BioKangtai DPT Series Vaccine Product Portfolio
  36. 8.6.5 BioKangtai Recent Developments
  37. 8.7 CanSino Biologics
  38. 8.7.1 CanSino Biologics Company Information
  39. 8.7.2 CanSino Biologics Business Overview
  40. 8.7.3 CanSino Biologics DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CanSino Biologics DPT Series Vaccine Product Portfolio
  42. 8.7.5 CanSino Biologics Recent Developments
  43. 8.8 Walvax Biotechnology
  44. 8.8.1 Walvax Biotechnology Company Information
  45. 8.8.2 Walvax Biotechnology Business Overview
  46. 8.8.3 Walvax Biotechnology DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Walvax Biotechnology DPT Series Vaccine Product Portfolio
  48. 8.8.5 Walvax Biotechnology Recent Developments
  49. 8.9 CNBG
  50. 8.9.1 CNBG Company Information
  51. 8.9.2 CNBG Business Overview
  52. 8.9.3 CNBG DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CNBG DPT Series Vaccine Product Portfolio
  54. 8.9.5 CNBG Recent Developments
  55. 8.10 Chongqing Zhifei Biological Products
  56. 8.10.1 Chongqing Zhifei Biological Products Company Information
  57. 8.10.2 Chongqing Zhifei Biological Products Business Overview
  58. 8.10.3 Chongqing Zhifei Biological Products DPT Series Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chongqing Zhifei Biological Products DPT Series Vaccine Product Portfolio
  60. 8.10.5 Chongqing Zhifei Biological Products Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DPT Series Vaccine Value Chain Analysis
  2. 9.1.1 DPT Series Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DPT Series Vaccine Sales Mode & Process
  6. 9.2 DPT Series Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DPT Series Vaccine Distributors
  9. 9.2.3 DPT Series Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst